The Latest Hypertension Industry Statistics Explained
Hypertension affects 1.13 billion people — nearly 1 in 4 men and 1 in 5 women globally.
The statistic that hypertension affects 1.13 billion people globally, with nearly 1 in 4 men and 1 in 5 women being affected, highlights the significant prevalence of this condition on a global scale. Hypertension, commonly known as high blood pressure, is a major risk factor for cardiovascular diseases and other health complications. The disparity in prevalence between men and women suggests potential differences in risk factors or healthcare-seeking behaviors. These findings underscore the importance of public health efforts to raise awareness, promote lifestyle modifications, and enhance access to healthcare services for the prevention, management, and treatment of hypertension to mitigate its impact on population health worldwide.
The global hypertension drugs market was valued at about $24.9 billion in 2020.
The statistic ‘The global hypertension drugs market was valued at about $24.9 billion in 2020’ indicates the total monetary worth of pharmaceutical products specifically aimed at treating high blood pressure worldwide during the year 2020. This value represents the revenue generated from the sale of various types of medications used for the management and treatment of hypertension, which is a common chronic medical condition affecting a significant proportion of the global population. The substantial market size reflects the high demand for hypertension drugs due to the prevalence of the condition and the importance of controlling blood pressure to prevent associated health risks.
North America has the highest market share in the global hypertension drugs market.
The statistic that North America has the highest market share in the global hypertension drugs market indicates that a significant portion of sales and revenue generated from hypertension medications comes from this region. This suggests that North America, which comprises countries such as the United States and Canada, has a relatively higher demand for hypertension drugs compared to other regions around the world. Factors contributing to this may include a larger population at risk of hypertension, higher healthcare spending and accessibility to medications, as well as the prevalence of the condition within the population. This statistic highlights the importance of North America as a key market for pharmaceutical companies operating in the hypertension drug sector and underscores the need for tailored strategies to address the specific needs and preferences of this market segment.
In the US, only 24% of adults with hypertension have their condition under control.
This statistic indicates that a significant proportion of adults in the United States who have hypertension, a condition characterized by high blood pressure, are not effectively managing their condition. With only 24% of individuals with hypertension having their condition under control, there is a substantial gap in the management of this chronic disease. Poorly controlled hypertension can lead to serious health complications such as heart disease, stroke, and kidney problems. This statistic highlights the importance of addressing barriers to effective hypertension management and improving access to healthcare services and interventions to better control blood pressure levels for a healthier population.
Hypertension prevalence is highest in Africa, where it affects 27% of adults.
The statistic states that the prevalence of hypertension is highest in Africa, affecting 27% of adults in the region. This implies that approximately one in four adults in Africa have been diagnosed with hypertension, a chronic condition characterized by elevated blood pressure levels. The high prevalence of hypertension in Africa is concerning as it is a major risk factor for cardiovascular diseases like heart attack and stroke. Factors contributing to this high prevalence may include changes in lifestyle, unhealthy diets, limited access to healthcare and treatment, as well as genetic predispositions. Efforts to address hypertension in Africa are crucial to improving public health outcomes and reducing the burden of cardiovascular diseases on the population.
By 2023, it’s projected that over 25% of the world’s population will be living with hypertension.
The statistic stating that by 2023, over 25% of the world’s population will be living with hypertension represents a significant global health concern. Hypertension, also known as high blood pressure, is a common condition that can lead to serious health complications such as heart disease, stroke, and kidney failure if left untreated. The projection suggests a substantial increase in the prevalence of hypertension worldwide, highlighting the need for concerted efforts in preventive healthcare, public health initiatives, and improved access to healthcare services to address this growing burden on global health systems and populations. Understanding and addressing the risk factors associated with hypertension, such as poor diet, lack of physical activity, and genetic predisposition, will be crucial in mitigating the impact of this chronic condition on individual health outcomes and overall public health.
Only about 50% of people with hypertension worldwide receive treatment.
This statistic indicates that approximately half of all individuals diagnosed with hypertension globally do not receive any form of treatment for their condition. Hypertension, also known as high blood pressure, is a significant risk factor for various health complications such as heart disease, stroke, and kidney damage. The fact that only half of those with hypertension are receiving treatment suggests a concerning gap in healthcare access and management of this chronic condition. Addressing this issue is crucial to ensure better health outcomes and reduce the burden of hypertension-related complications on individuals and healthcare systems worldwide.
In 2019, the global hypertension management devices market was valued at USD 732.8 million.
The statistic states that in the year 2019, the market for hypertension management devices around the world was estimated to be worth USD 732.8 million. This figure represents the total monetary value of all sales of devices used for managing hypertension, such as blood pressure monitors, digital sphygmomanometers, and other related products. The size of this market indicates the demand and level of investment in technologies and products aimed at diagnosing and controlling high blood pressure, a common medical condition with significant implications for public health. This information provides insight into the scale and importance of the hypertension management industry globally.
The hypertension management devices market is projected to grow at a CAGR of 11.2% from 2020-2027.
This statistic indicates that the market for hypertension management devices is expected to experience significant growth between 2020 and 2027, with a compound annual growth rate (CAGR) of 11.2%. This suggests a consistent year-on-year increase in market size and demand for devices used in managing hypertension over the specified period. Factors driving this growth may include a rising prevalence of hypertension globally, technological advancements in healthcare devices, increasing adoption of home monitoring solutions, and a growing emphasis on preventive healthcare. The projected growth rate of 11.2% indicates a strong market potential and opportunities for companies operating in the hypertension management devices sector.
In 2020, Novartis AG, Sanofi S.A., Pfizer Inc., Daiichi Sankyo Company, and Boehringer Ingelheim international GmbH were the leading players in the global hypertension drugs market.
The statistic states that in 2020, Novartis AG, Sanofi S.A., Pfizer Inc., Daiichi Sankyo Company, and Boehringer Ingelheim International GmbH were the top companies in the global market for hypertension drugs, indicating that they had the highest market shares and revenues within the industry. This suggests that these companies likely had a significant presence in terms of manufacturing, marketing, and distributing medications used to treat hypertension. Their prominence in the market indicates they are major players in the healthcare industry, with a strong focus on developing and providing pharmaceutical solutions for managing high blood pressure, a common health condition worldwide.
In 2020, the Asia Pacific region held the largest share in the hypertension management devices market.
In 2020, the Asia Pacific region held the largest share in the hypertension management devices market, indicating that the majority of sales and usage of such medical devices occurred in countries within the Asia Pacific region compared to other regions globally. This statistic suggests a higher prevalence or awareness of hypertension management in the region, leading to increased demand for related devices. Factors such as the aging population, changing lifestyles, and increasing healthcare expenditure may have contributed to the significant market share in the Asia Pacific region for hypertension management devices in 2020. Further analysis may be needed to understand specific drivers behind this trend and to identify growth opportunities within this market sector.
It is estimated that by 2030, 23.6 million people will die from their cardiovascular disease annually, mainly due to stroke and heart disease.
The statistic estimates that by the year 2030, a staggering 23.6 million individuals worldwide will succumb to cardiovascular diseases on an annual basis, with the primary culprits being stroke and heart disease. This represents a significant global health challenge, as cardiovascular diseases continue to be a leading cause of mortality across the globe. The prediction underscores the urgent need for comprehensive prevention and intervention strategies to effectively address the risk factors and underlying causes of these diseases, in order to curb the alarming trend of cardiovascular-related deaths and improve public health outcomes on a global scale.
The hypertension drugs market in the Middle East & Africa is projected to grow at a CAGR of 5.07% from 2021-2030.
The statistic indicates that the market for hypertension drugs in the Middle East & Africa region is expected to experience steady growth over the period from 2021 to 2030, with a Compound Annual Growth Rate (CAGR) of 5.07%. This projection suggests that there will be an increasing demand for hypertension medications in the region due to factors such as an aging population, changing lifestyles, rising prevalence of hypertension, and improved access to healthcare services. The CAGR of 5.07% reflects the expected average annual growth rate of the market size for hypertension drugs during this timeframe, indicating a positive trend for pharmaceutical companies operating in this market and potentially offering investment opportunities in the healthcare sector.
The prevalence of hypertension in low-income countries is 40%, which is higher than in high-income countries (35%).
The statistic highlights the disparity in hypertension prevalence between low-income and high-income countries. It indicates that a larger proportion of individuals in low-income countries (40%) are affected by hypertension compared to those in high-income countries (35%). This suggests that socioeconomic factors play a role in the prevalence of hypertension, with individuals in low-income countries being at a higher risk. The higher prevalence in low-income countries may be attributed to factors such as limited access to healthcare, lower awareness about the condition, poorer dietary habits, and higher levels of stress. Addressing these disparities is crucial for improving public health outcomes and reducing the burden of hypertension globally.
The hypertensive population of China is projected to reach 244 million in 2021.
The statistic indicates that the number of people with hypertension in China is expected to increase to 244 million in the year 2021. This projection suggests a significant rise in the hypertensive population compared to previous years, highlighting the growing public health concern of high blood pressure in China. As hypertension is a major risk factor for cardiovascular diseases and other serious health conditions, this statistic underscores the importance of implementing effective preventive measures and strategies to manage and reduce the prevalence of hypertension in the country.
The antihypertensive drugs market in China is expected to grow at a CAGR of 6.3% from 2021 to 2027.
The statement that the antihypertensive drugs market in China is expected to grow at a compound annual growth rate (CAGR) of 6.3% from 2021 to 2027 indicates the projected average annual rate of growth for the market over this period. This statistic suggests that there will be a consistent and steady increase in the market size for antihypertensive drugs in China, reflecting factors such as an aging population, increasing prevalence of hypertension, improving healthcare infrastructure, and rising awareness about the importance of managing high blood pressure. The CAGR of 6.3% serves as a key indicator for stakeholders in the pharmaceutical industry, investors, and policymakers to anticipate and plan for the growth trajectory of the antihypertensive drugs market in China over the specified time frame.
As of 2020, more than 75% of Americans aged 65 and over have hypertension.
The statistic “As of 2020, more than 75% of Americans aged 65 and over have hypertension” indicates that a significant majority of individuals in the United States who are 65 years of age and older experience high blood pressure. Hypertension, or high blood pressure, is a common health condition that can increase the risk of serious health problems such as heart disease and stroke. This statistic highlights the prevalence of hypertension among older Americans, emphasizing the importance of proper management and control of blood pressure through lifestyle modifications and medical interventions to reduce the associated health risks and improve overall health outcomes in this demographic group.
Conclusion
Our exploration of hypertension industry statistics has revealed valuable insights into the prevalence, treatment options, and future trends of this prevalent health condition. By understanding the data and trends within the industry, healthcare professionals and policymakers can better address the challenges posed by hypertension and work towards improving the health outcomes of individuals worldwide.
References
0. – https://www.www.researchandmarkets.com
1. – https://www.www.who.int
2. – https://www.www.thebusinessresearchcompany.com
3. – https://www.www.heart.org
4. – https://www.www.afro.who.int
5. – https://www.www.globenewswire.com
6. – https://www.www.grandviewresearch.com
